U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H22N4O5
Molecular Weight 386.4018
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MK-6892

SMILES

CC(C)(CC1=NC(=NO1)C2=NC=C(O)C=C2)C(=O)NC3=C(CCCC3)C(O)=O

InChI

InChIKey=CJHXBFSJXDUJHP-UHFFFAOYSA-N
InChI=1S/C19H22N4O5/c1-19(2,18(27)21-13-6-4-3-5-12(13)17(25)26)9-15-22-16(23-28-15)14-8-7-11(24)10-20-14/h7-8,10,24H,3-6,9H2,1-2H3,(H,21,27)(H,25,26)

HIDE SMILES / InChI
Molecular Formula C19H22N4O5
Molecular Weight 386.4018
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

MK-6892 is niacin receptor 2 agonist, developed by Merkc. In preclinical experiments, it demonstrated reduction of free fatty acid levels by ~85%, with flushing side-effect evident only at the highest dose tested.

Originator

Merck
238
Curator's Comment: # Merck

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 4.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.
2010-03-25
Patents

Patents

WO-2007002557-A1
1

Sample Use Guides

In Vivo Use Guide
In preclinical experiments MK-6892 was administered to rats at doses between 1 and 100 mg/kg. Compound was administered orally. Plasma free fatty acid levels and vasodilation was monitored.
Route of Administration: Oral
In Vitro Use Guide
Binding to niacin receptor 2 was measured by 3H-NA competition. In these experiments Ki was found to be 4.0 nM (595 nM in 4% human serum). In the guanine nucleotide exchange (GTPγS) assays with membranes from CHO cells expressing the recombinant human GPR109A, the functional activity of GPR109A agonists was determined.
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:04:50 GMT 2025
Edited
by admin
on Mon Mar 31 21:04:50 GMT 2025
Record UNII
PH9ZB6IRW0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MK-6892
Common Name English
1-CYCLOHEXENE-1-CARBOXYLIC ACID, 2-((3-(3-(5-HYDROXY-2-PYRIDINYL)-1,2,4-OXADIAZOL-5-YL)-2,2-DIMETHYL-1-OXOPROPYL)AMINO)-
Preferred Name English
Code System Code Type Description
PUBCHEM
135416394
Created by admin on Mon Mar 31 21:04:50 GMT 2025 , Edited by admin on Mon Mar 31 21:04:50 GMT 2025
PRIMARY
FDA UNII
PH9ZB6IRW0
Created by admin on Mon Mar 31 21:04:50 GMT 2025 , Edited by admin on Mon Mar 31 21:04:50 GMT 2025
PRIMARY
CAS
917910-45-3
Created by admin on Mon Mar 31 21:04:50 GMT 2025 , Edited by admin on Mon Mar 31 21:04:50 GMT 2025
PRIMARY
Related Record Type Details
Structure of MK-6892
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966